GTx (GTXI) +10.3% premarket after saying the FDA removed its Full Clinical Hold on its...

|By:, SA News Editor

GTx (GTXI) +10.3% premarket after saying the FDA removed its Full Clinical Hold on its Investigational New Drug application for prostate cancer treatment Capesaris. During Q3, GTXI expects to initiate a Phase II clinical study of Capesaris as a secondary hormonal therapy in men with certain kinds of prostate cancer. (also: earnings)